NO20043119L - Triazolokinolinderivater som kan anvendes som adenosinreseptorligander - Google Patents
Triazolokinolinderivater som kan anvendes som adenosinreseptorliganderInfo
- Publication number
- NO20043119L NO20043119L NO20043119A NO20043119A NO20043119L NO 20043119 L NO20043119 L NO 20043119L NO 20043119 A NO20043119 A NO 20043119A NO 20043119 A NO20043119 A NO 20043119A NO 20043119 L NO20043119 L NO 20043119L
- Authority
- NO
- Norway
- Prior art keywords
- receptor ligands
- adenosine receptor
- triazoloquinoline
- derivatives
- triazoloquinoline derivatives
- Prior art date
Links
- FGLRGMVWMQLOCO-UHFFFAOYSA-N 2h-triazolo[4,5-h]quinoline Chemical class C1=CC2=CC=CN=C2C2=C1N=NN2 FGLRGMVWMQLOCO-UHFFFAOYSA-N 0.000 title 1
- 102000009346 Adenosine receptors Human genes 0.000 title 1
- 108050000203 Adenosine receptors Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105407A HUP0105407A3 (en) | 2001-12-21 | 2001-12-21 | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| PCT/HU2002/000143 WO2003053968A1 (en) | 2001-12-21 | 2002-12-17 | Triazolo-quinolin derivatives useful as adenosine receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043119L true NO20043119L (no) | 2004-07-20 |
| NO329757B1 NO329757B1 (no) | 2010-12-13 |
Family
ID=90001529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043119A NO329757B1 (no) | 2001-12-21 | 2004-07-20 | Triazolokinolinderivater som kan anvendes som adenosinreseptorligander, fremgangsmate for fremstilling derav, mellomprodukter i fremgangsmaten, farmasoytiske preparater som inneholder forbindelsene og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7365089B2 (no) |
| EP (1) | EP1456204A1 (no) |
| JP (2) | JP4724366B2 (no) |
| KR (1) | KR100934796B1 (no) |
| CN (1) | CN1307175C (no) |
| AU (1) | AU2002353240B2 (no) |
| BR (1) | BR0215276A (no) |
| CA (1) | CA2470064C (no) |
| EA (1) | EA007066B1 (no) |
| HR (1) | HRP20040672A2 (no) |
| HU (2) | HUP0105407A3 (no) |
| IL (2) | IL162444A0 (no) |
| IS (1) | IS7318A (no) |
| MA (1) | MA27094A1 (no) |
| MX (1) | MXPA04006113A (no) |
| NO (1) | NO329757B1 (no) |
| NZ (1) | NZ534016A (no) |
| PL (1) | PL370747A1 (no) |
| RS (1) | RS56004A (no) |
| TN (1) | TNSN04106A1 (no) |
| UA (1) | UA79955C2 (no) |
| WO (1) | WO2003053968A1 (no) |
| ZA (1) | ZA200404802B (no) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
| US20050288502A1 (en) * | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| CN102702314A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsr、制备和应用 |
| CN102702316A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdfyigsk、制备和应用 |
| CN102702315A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdsyigsk、制备和应用 |
| CN102702313A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsr、制备和应用 |
| CN102702312A (zh) * | 2006-11-30 | 2012-10-03 | 首都医科大学 | 具有靶向抗血栓活性的rgdvyigsk、制备和应用 |
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| BR112015018282B1 (pt) | 2013-02-01 | 2021-08-24 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| CN108358927B (zh) * | 2018-01-26 | 2020-09-01 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE280109C (no) | ||||
| DE280110C (no) | ||||
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| DD280110A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung von 1.2.4-triazolo/1.5-a/-pyridin-8-carbonitrilen |
| DD280109A1 (de) * | 1989-02-22 | 1990-06-27 | Univ Berlin Humboldt | Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine |
| DE3926770A1 (de) * | 1989-08-12 | 1991-02-14 | Basf Ag | (1,2,4)triazolo(1,5-a)pyridine |
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
| US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| HUP0105407A3 (en) | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
-
2001
- 2001-12-21 HU HU0105407A patent/HUP0105407A3/hu unknown
-
2002
- 2002-12-17 WO PCT/HU2002/000143 patent/WO2003053968A1/en active IP Right Grant
- 2002-12-17 BR BR0215276-2A patent/BR0215276A/pt not_active IP Right Cessation
- 2002-12-17 EP EP02788260A patent/EP1456204A1/en not_active Withdrawn
- 2002-12-17 NZ NZ534016A patent/NZ534016A/en not_active IP Right Cessation
- 2002-12-17 KR KR1020047009789A patent/KR100934796B1/ko not_active IP Right Cessation
- 2002-12-17 IL IL16244402A patent/IL162444A0/xx unknown
- 2002-12-17 EA EA200400848A patent/EA007066B1/ru not_active IP Right Cessation
- 2002-12-17 UA UA20040706067A patent/UA79955C2/uk unknown
- 2002-12-17 US US10/499,250 patent/US7365089B2/en not_active Expired - Fee Related
- 2002-12-17 CA CA2470064A patent/CA2470064C/en not_active Expired - Fee Related
- 2002-12-17 MX MXPA04006113A patent/MXPA04006113A/es active IP Right Grant
- 2002-12-17 HU HU0402282A patent/HUP0402282A3/hu unknown
- 2002-12-17 AU AU2002353240A patent/AU2002353240B2/en not_active Ceased
- 2002-12-17 PL PL02370747A patent/PL370747A1/xx not_active Application Discontinuation
- 2002-12-17 CN CNB028256468A patent/CN1307175C/zh not_active Expired - Fee Related
- 2002-12-17 RS YU56004A patent/RS56004A/sr unknown
- 2002-12-17 JP JP2003554684A patent/JP4724366B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-07 MA MA27724A patent/MA27094A1/fr unknown
- 2004-06-08 TN TNP2004000106A patent/TNSN04106A1/en unknown
- 2004-06-10 IL IL162444A patent/IL162444A/en not_active IP Right Cessation
- 2004-06-16 IS IS7318A patent/IS7318A/is unknown
- 2004-06-17 ZA ZA200404802A patent/ZA200404802B/en unknown
- 2004-07-20 NO NO20043119A patent/NO329757B1/no not_active IP Right Cessation
- 2004-07-20 HR HR20040672A patent/HRP20040672A2/xx not_active Application Discontinuation
-
2008
- 2008-02-28 US US12/039,272 patent/US7713992B2/en not_active Expired - Fee Related
-
2010
- 2010-09-08 JP JP2010200550A patent/JP2011042653A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1414440T3 (da) | N-phenylpyrrolguanidinderivater som melanocortinreceptorligander | |
| ATE319451T1 (de) | Tetrahydrochinolin-derivate | |
| DK1419152T3 (da) | HIV-hæmmende pyrimidin-derivater | |
| NO20042279L (no) | Kinazolinderivater som antitumormidler | |
| NO20042288L (no) | Kinazolinderivater som antitumormidler | |
| ATE312827T1 (de) | 3-substituierte-4-pyrimidonderivate | |
| NO20034439D0 (no) | Benzamidinderivater | |
| ATE309245T1 (de) | 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate | |
| NO20033572D0 (no) | Viskoelastiske blandinger | |
| NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
| NO20044654L (no) | Piperidinoylpiperidiner som 5-HTIF-agonister | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| DK1456206T3 (da) | Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| NO20052866D0 (no) | Imidazokinolinderivater som adenosin A3 reseptorligander | |
| DK1455779T3 (da) | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| ATE306265T1 (de) | Benzothiazolderivate als adenosin-rezeptor- liganden | |
| EE200300447A (et) | Asendatud bensofuraan-2-karboksamiidide derivaadid | |
| NO20014597D0 (no) | Fremgangsmåte | |
| NO20043119L (no) | Triazolokinolinderivater som kan anvendes som adenosinreseptorligander | |
| DE60223031D1 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
| DK1347974T3 (da) | Aminotriazolopyridinderivater som adenosinreceptorligander | |
| NO20035206D0 (no) | Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer | |
| DK1636223T3 (da) | Benzothiazolderivater som adenosinreceptorligander | |
| ATE382601T1 (de) | Substituierte 4-aminocyclohexanolderivate | |
| DE60202381D1 (de) | Paroxetin-n-formyl-derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |